Replies to post #83394 on Biotech Values

[DewDiligence]

Survey on FTY720 ‘FREEDOMS’ Data in MS

Background: NVS reports FTY720 data from the phase-3 FREEDOMS trial at the ECTRIMS conference tomorrow. Unlike the successful TRANFORMS trial (#msg-34138493), FREEDOMS includes 24 months of treatment, and hence (if successful) it meets the duration requirement for an agent to be considered disease modifying in MS.

Note: the comparator in the FREEDOMS trial is placebo. (In the TRANSFORMS trial, the comparator was Avonex.)


Q: What is your expectation for the FREEDOMS trial?

a) Unmitigated success.
b) Unmitigated failure.
c) A mixed bag.


To vote, please go to
http://investorshub.advfn.com/boards/board_surveymenu.asp?board_id=1418
and select survey #128.

[DewDiligence]

NVS’ FTY720 presentation on the FREEDOMS trial at the ECTRIMS conference has evidently been rescheduled. I presume the data will be out this weekend.

There’s still time for readers to vote in the FTY720 survey in #msg-41325666.